Digoxin Toxicity — Digoxin Immune Fab

Key Points

• Digoxin toxicity may be acute or chronic, and chronic toxicity can be clinically important at only modestly elevated serum concentrations.
• Hyperkalemia is a marker of severe acute digoxin poisoning, while hypokalemia can increase susceptibility to chronic toxicity.
• Life-threatening arrhythmia, hemodynamic instability, cardiac arrest, or severe acute toxicity are indications for digoxin immune Fab.
• Do not delay Fab while pursuing less definitive rhythm interventions in an unstable patient.
• Total digoxin concentrations become difficult to interpret after Fab administration.
• Potassium can fall quickly after effective Fab therapy and must be monitored.
• Hemodialysis and related extracorporeal techniques are not effective digoxin-removal strategies.
• Renal dysfunction is a major driver of chronic accumulation and can prolong Fab-digoxin complex clearance.

Algorithm

1. Assess airway, circulation, mental status, and rhythm; place symptomatic patients on continuous cardiac monitoring.
2. Obtain ECG, potassium, magnesium, calcium, renal function, glucose, and a digoxin concentration when useful.
3. Determine whether toxicity is acute, chronic, or acute-on-chronic and identify interacting drugs or renal decline.
4. Correct important potassium and magnesium abnormalities and treat shock supportively.
5. Administer digoxin immune Fab promptly for life-threatening dysrhythmia, severe bradycardic instability, shock, cardiac arrest, or severe acute toxicity.
6. Use atropine for symptomatic bradycardia and consider lidocaine or phenytoin for ventricular dysrhythmia while Fab is being obtained or taking effect.
7. Reserve pacing or cardioversion for situations where immediate rhythm rescue is necessary and Fab alone cannot be awaited.
8. Reassess rhythm, perfusion, potassium, renal function, and symptoms after Fab.
9. Do not use dialysis solely to remove digoxin.
10. Admit significant symptomatic toxicity for monitored care and address the cause of accumulation before restarting therapy.

Clinical Synopsis & Reasoning

Digoxin toxicity can be acute after a large ingestion or chronic from accumulation during therapy. Chronic toxicity is especially important in older adults and patients with renal impairment, dehydration, low body mass, or interacting medications. Symptoms are often nonspecific and include anorexia, nausea, vomiting, abdominal discomfort, fatigue, weakness, confusion, and visual disturbance. Cardiovascular toxicity ranges from sinus bradycardia and AV block to atrial tachyarrhythmias with block, ventricular ectopy, ventricular tachycardia, ventricular fibrillation, and cardiac arrest.

Acute and chronic toxicity differ physiologically. Acute poisoning can cause substantial hyperkalemia because Na/K ATPase inhibition shifts potassium extracellularly, and severe hyperkalemia correlates with toxicity severity. Chronic toxicity can occur at only modestly elevated measured digoxin concentrations and may coexist with hypokalemia or hypomagnesemia from diuretics, which increases myocardial sensitivity to digoxin. Renal dysfunction prolongs elimination.

A digoxin concentration is useful only when interpreted correctly. Blood drawn soon after a therapeutic dose or acute ingestion may be misleading because distribution into tissues is incomplete. In chronic toxicity, symptoms, renal function, potassium, ECG abnormalities, and trend matter more than a rigid concentration threshold. After digoxin immune Fab is given, standard total digoxin assays become difficult to interpret because they measure Fab-bound as well as free drug. Management should then be guided by clinical response rather than total concentration.

Treatment Strategy & Disposition

Stabilize airway, breathing, and circulation and place symptomatic patients on continuous ECG monitoring. Check potassium, magnesium, calcium, renal function, glucose, and acid-base status, and obtain serial ECGs. Correct hypokalemia and hypomagnesemia cautiously when present because both increase dysrhythmia risk. Avoid unnecessary calcium restriction in routine care, but hyperkalemia from severe acute digoxin poisoning should prompt definitive Fab therapy rather than relying on temporizing electrolyte measures alone.

The 2025 American Heart Association guideline recommends digoxin-specific antibody fragments for adults and children with life-threatening digoxin or digitoxin poisoning. Indications include dangerous ventricular dysrhythmia, severe bradyarrhythmia or high-grade block with hemodynamic compromise, cardiac arrest, shock, and severe acute poisoning with hyperkalemia. Dosing can be calculated from the known amount ingested or measured steady-state concentration when reliable, or given empirically when the exposure is unknown and the patient is unstable. Clinical improvement in arrhythmia and hemodynamics often occurs within tens of minutes.

Atropine may be used as part of standard bradycardia care, although response can be variable. Temporary pacing can be difficult and may provoke ventricular dysrhythmia in severe digoxin toxicity, so Fab should not be delayed while attempting repeated pacing interventions. Lidocaine or phenytoin may be considered for life-threatening ventricular arrhythmias while Fab is being obtained or taking effect. Electrical cardioversion is reserved for immediately life-threatening unstable dysrhythmia and should use the lowest effective energy when possible because the myocardium can be highly irritable.

Hemodialysis, hemofiltration, hemoperfusion, and plasmapheresis are not recommended as methods of digoxin removal because of digoxin's large volume of distribution. After Fab, monitor for recurrent toxicity in patients with severe renal failure because Fab-digoxin complexes can persist. Potassium can fall rapidly after successful Fab treatment as Na/K ATPase function recovers, so serial potassium measurement is important.

Epidemiology / Risk Factors

• Digoxin is used less widely than in previous decades but remains important in selected patients with atrial fibrillation and heart failure.
• Chronic toxicity is common in older adults with declining renal function or medication interactions.
• Acute intentional ingestion can produce severe hyperkalemia and malignant dysrhythmias.
• Low body mass, dehydration, kidney disease, and interacting medications increase toxicity risk at therapeutic dosing.
• Plant and animal cardiac glycosides can produce a similar toxidrome and may also respond to digoxin Fab.

Investigations

When to Give Fab (Abbrev.)

Pharmacology

Prognosis / Complications

• Life-threatening toxicity often improves rapidly after timely digoxin immune Fab.
• Cardiac arrest, profound hyperkalemia, refractory ventricular dysrhythmia, and delayed antidote administration worsen prognosis.
• Chronic toxicity generally resolves when Fab is given when indicated and the precipitating renal or medication problem is corrected.
• Renal failure can prolong monitoring needs after Fab.
• Patients without hypoxic injury or persistent organ failure usually recover without lasting toxic effects.

Patient Education / Counseling

• Review the exact digoxin dose and administration schedule before discharge.
• Explain that dehydration, kidney injury, and new medications can increase digoxin levels.
• Advise prompt evaluation for new nausea, confusion, severe weakness, fainting, palpitations, or marked bradycardia.
• Ensure patients know when renal function and digoxin concentrations should be rechecked after medication changes.
• Use a medication list to prevent interactions and accidental duplicate dosing.
• Do not restart digoxin after serious toxicity until the indication, dose, kidney function, and interacting medications have been reassessed.

Notes

Digoxin toxicity is one of the clearest examples of why a laboratory value cannot replace bedside toxicology. The same measured concentration can have very different significance depending on timing, acute versus chronic exposure, renal function, and electrolyte status. After Fab, total digoxin concentration becomes even less useful.

The 2025 AHA guideline gives digoxin-specific immune Fab a strong recommendation for life-threatening poisoning and specifically recommends against extracorporeal removal techniques for digoxin because the drug is not effectively cleared that way.

References

1. American Heart Association 2025 Guidelines: Digoxin and Related Cardiac Glycosides — Link